1. A method of treating breast cancer or tumor comprising administering, to a subject in need of such treatment, an effective amount of a PKC-iota inhibitor, and, optionally, a pharmaceutical acceptable carrier.
2. The method according to claim 1, wherein the subject is a human.
3. The method according to claim 1, wherein the PKC-iota inhibitor is selected from:
a) a compound of Formula (I) or a salt thereof, wherein the compound of formula (I) is:
wherein R1 and R2 are, independently, \u2014NH2 or alkylamino, and
wherein R3 and R4 are, independently, \u2014H, \u2014OH, alkoxy, or \u2014OC(O)R\u2032,
wherein R\u2032 is a linear saturated monovalent radical of one to eight carbon atoms or a branched saturated monovalent of three to eight carbon atoms;
b) an antibody, aptamer, or binding partner that binds specifically to PKC-\u03b9, or a fusion construct comprising said antibody, aptamer, or binding partner; or
c) an antisense polynucleotide that specifically targets PKC-\u03b9 mRNA.
4. The method of claim 3, wherein the PKC-iota inhibitor is a compound of Formula (I), or a salt thereof.
5. The method of claim 4, wherein the PKC-iota inhibitor is (1H-imidazole-4-carboxamide,5-amino-1-2,3-dihydroxy-4-(phosphonooxy)methylcyclopentyl-,1R-(1\u03b1, 2\u03b2, 3\u03b2, 4\u03b1) (ICA-1), or a salt thereof.
6. The method of claim 3, wherein the PKC-iota inhibitor is an antibody that binds specifically to a PKC-\u03b9 polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:1, wherein the PKC-\u03b9 polypeptide comprises a catalytic domain that is amino acid residues 469-475 of SEQ ID NO:1 (glutamine-469, isoleucine-470, arginine-471, isoleucine-472, proline-473, arginine-474, serine- 475).
7. The method of claim 6, wherein the PKC-\u03b9 polypeptide comprises SEQ ID NO:1.
8. The method of claim 3, wherein the PKC-iota inhibitor is an antisense polynucleotide that specifically targets PKC-\u03b9 mRNA, wherein the PKC-\u03b9 mRNA encodes a PKC-\u03b9 polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:1, wherein the PKC-\u03b9 polypeptide comprises a catalytic domain that is amino acid residues 469-475 of SEQ ID NO:1 (glutamine-469, isoleucine-470, arginine-471, isoleucine-472, proline-473, arginine-474, serine- 475).
9. The method of claim 8, wherein the PKC-\u03b9 polypeptide comprises SEQ ID NO:1.
10. The method of claim 1, wherein the subject has breast cancer.
11. The method of claim 10, wherein the subject has ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), lobular carcinoma in-situ (LCIS), invasive lobular carcinoma (LCIS), medullary carcinoma, malignant phyllode tumor, tubular carcinoma, mucinous carcinoma, metastatic adenocarcinoma, or inflammatory breast cancer.
12. The method of claim 11, wherein the subject has invasive ductal carcinoma, invasive lobular carcinoma, or metastatic adenocarcinoma.
13. A method of inhibiting proliferation of breast cancer or tumor cells, comprising administering to the breast cancer or tumor cells an effective amount of a PKC-iota inhibitor, and optionally, a pharmaceutically acceptable carrier.
14. The method according to claim 13, wherein the PKC-iota inhibitor is selected from:
a) a compound of formula (I) or a salt thereof, wherein the compound of formula (I) is:
wherein R1 and R2 are, independently, \u2014NH2 or alkylamino, and
wherein R3 and R4 are, independently, \u2014H, \u2014OH, alkoxy, or \u2014OC(O)R\u2032,
wherein R\u2032 is a linear saturated monovalent radical of one to eight carbon atoms or a branched saturated monovalent of three to eight carbon atoms;
b) an antibody, aptamer, or binding partner that binds specifically to PKC-\u03b9, or a fusion construct comprising said antibody, aptamer, or binding partner; or
c) an antisense polynucleotide that specifically targets PKC-\u03b9 mRNA.
15. The method of claim 14, wherein the PKC-iota inhibitor is a compound of Formula (I), or a salt thereof.
16. The method of claim 15, wherein the PKC-iota inhibitor is (1H-imidazole-4-carboxamide, 5-amino-1-2,3 -dihydroxy-4-(phosphonooxy) methylcyclopentyl1R-(1\u03b1, 2\u03b2, 3\u03b2, 4\u03b1) (ICA-1), or a salt thereof.
17. The method of claim 14, wherein the PKC-iota inhibitor is an antibody that binds specifically to a PKC-\u03b9 polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:1, wherein the PKC-\u03b9 polypeptide comprises a catalytic domain that is amino acid residues 469-475 of SEQ ID NO:1 (glutamine-469, isoleucine-470, arginine-471, isoleucine-472, proline-473, arginine-474, serine- 475).
18. The method of claim 14, wherein the PKC-iota inhibitor is an antisense polynucleotide that specifically targets PKC-\u03b9 mRNA, wherein the PKC-\u03b9 mRNA encodes a PKC-\u03b9 polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:1, wherein the PKC-\u03b9 polypeptide comprises a catalytic domain that is amino acid residues 469-475 of SEQ ID NO:1 (glutamine-469, isoleucine-470, arginine-471, isoleucine-472, proline-473, arginine-474, serine- 475).
19. The method of claim 13, wherein the breast cancer or tumor cells are of human origin.
20. The method of claim 19, wherein the breast cancer or tumor cells are selected from non-invasive ductal carcinoma cells, invasive ductal carcinoma cells, non-invasive lobular carcinoma cells, invasive lobular carcinoma cells, medullary carcinoma cells, malignant phyllode tumor cells, tubular carcinoma cells, mucinous carcinoma cells, metastatic adenocarcinoma cells, or inflammatory breast cancer cells.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A non-aqueous capacitor comprising an electrode unit composed of collectors, electrodes and separators, and an electrolytic solution, which are contained and sealed in a case, characterized in that each of the collectors, electrodes and separators is made of the material(s) having a melting point or pyrolysis-initiating temperature (where melting point is not expressed) not lower than 280\xb0 C., and that the electrode unit is dried after its assembling, at a temperature not lower than the lowest of the melting points or pyrolysis-initiating temperatures of the materials constituting the electrode unit, by 100\xb0 C.
2. A non-aqueous capacitor according to claim 1, in which each of the collectors, electrodes and separators is made of the materials having a melting point or pyrolysis-initiating temperature (where melting point is not expressed) not lower than 320\xb0 C.
3. A non-aqueous capacitor according to claim 1, in which the electrode unit is the one dried after its assembling, at a temperature not lower than the lowest of the melting points or pyrolysis-initiating temperatures (where melting point is not expressed) of the materials constituting the electrode unit by 50\xb0 C.
4. A non-aqueous capacitor according to claim 1, in which the drying temperature is within a range not higher than 30\xb0 C. below the lowest of the melting points or pyrolysis-initiating temperatures (where melting point is not expressed) of the materials used in the collectors, electrodes and separators which constitute the electrode unit, but not lower than the said lowest temperature by 100\xb0 C.
5. A non-aqueous capacitor according to claim 4, in which the drying temperature is within a range not higher than 30\xb0 C. below the lowest of the melting points or pyrolysis-initiating temperatures (where melting point is not expressed) of the materials used in the collectors, electrodes and separators which constitute the electrode unit, but not lower than the said lowest temperature by 50\xb0 C.
6. A non-aqueous capacitor according to claim 1, in which the water content of the electrode after the drying is not more than 1700 ppm.
7. A non-aqueous capacitor according to claim 1, which has a capacity retention, after being kept in floating condition at a voltage of 2.8 V and a temperature of 70\xb0 C. for 500 hours, of at least 70%.
8. A method of manufacturing a non-aqueous capacitor comprising an electrode unit which is composed of collectors, electrodes and separators, the method being characterized by making each of the collectors, electrodes and separators of the materials having a melting point or pyrolysis-initiating temperature (where melting point is not expressed) not lower than 280\xb0 C., drying the electrode unit after its assembling at a temperature not lower than the lowest of the melting points or pyrolysis-initiating temperatures of the materials by 100\xb0 C., putting the dried electrode unit in a case, pouring an electrolytic solution thereinto and sealing the case.
9. The method according to claim 8, in which the drying is carried out until water content of the electrode becomes no more than 1700 ppm.